Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences in February 2025.
The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 9:20 a.m. ET through a virtual presentation. Additionally, Olema will participate in Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025, at 10 a.m. ET in a virtual fireside chat format.
Live webcasts of both presentations will be accessible through the Events and Presentations section of Olema's investor relations website at ir.olema.com, with recordings available for at least 30 days after the events.
Olema Pharmaceuticals (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica specializzata in terapie mirate per il cancro al seno, ha annunciato la sua partecipazione a due prossime conferenze per investitori a febbraio 2025.
L'azienda presenterà alla 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita mercoledì 12 febbraio 2025, alle 9:20 a.m. ET tramite una presentazione virtuale. Inoltre, Olema parteciperà al Summit Virtuale sulla Leadership Oncologica di Citi 2025 giovedì 20 febbraio 2025, alle 10 a.m. ET in un formato di chat informale virtuale.
Le dirette streaming di entrambe le presentazioni saranno accessibili attraverso la sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Olema all'indirizzo ir.olema.com, con registrazioni disponibili per almeno 30 giorni dopo gli eventi.
Olema Pharmaceuticals (Nasdaq: OLMA), una compañía biofarmacéutica en etapa clínica especializada en terapias dirigidas para el cáncer de mama, ha anunciado su participación en dos conferencias de inversionistas que se llevarán a cabo en febrero de 2025.
La compañía presentará en la 35ª Conferencia Anual Oppenheimer sobre Ciencias de la Salud el miércoles 12 de febrero de 2025, a las 9:20 a.m. ET a través de una presentación virtual. Además, Olema participará en el Summit Virtual de Liderazgo Oncológico de Citi 2025 el jueves 20 de febrero de 2025, a las 10 a.m. ET en un formato de charla informal virtual.
Las retransmisiones en vivo de ambas presentaciones estarán disponibles a través de la sección de Eventos y Presentaciones en el sitio web de relaciones con inversionistas de Olema en ir.olema.com, con grabaciones accesibles durante al menos 30 días después de los eventos.
Olema Pharmaceuticals (Nasdaq: OLMA)는 유선암을 위한 표적 치료제 전문의 임상 단계의 생물 의약품 회사로, 2025년 2월에 열리는 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 2025년 2월 12일 수요일 오전 9:20 ET에 Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에서 가상 발표를 통해 발표할 예정입니다. 추가로 Olema는 2025년 2월 20일 목요일 오전 10:00 ET에 Citi의 2025년 가상 종양학 리더십 정상 회담에 참여하여 가상 대화 형식으로 진행할 것입니다.
두 발표의 라이브 웹캐스트는 Olema의 투자자 관계 웹사이트 ir.olema.com의 이벤트 및 발표 섹션을 통해 접근할 수 있으며, 이벤트 종료 후 최소 30일 동안 녹화본이 제공됩니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour le cancer du sein, a annoncé sa participation à deux conférences pour investisseurs prévues en février 2025.
La société présentera lors de la 35ème Conférence Annuelle Oppenheimer sur les Sciences de la Vie le mercredi 12 février 2025, à 9h20 ET par le biais d'une présentation virtuelle. De plus, Olema participera au Sommet Virtuel sur le Leadership Oncologique de Citi 2025 le jeudi 20 février 2025, à 10h00 ET dans un format de discussion informelle virtuelle.
Les webcasts en direct des deux présentations seront accessibles via la section Événements et Présentations du site des relations investisseurs d'Olema à l'adresse ir.olema.com, avec des enregistrements disponibles pendant au moins 30 jours après les événements.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien gegen Brustkrebs spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Februar 2025 bekannt gegeben.
Das Unternehmen wird am Mittwoch, dem 12. Februar 2025, um 9:20 Uhr ET über eine virtuelle Präsentation auf der 35. jährlichen Oppenheimer Healthcare Life Sciences Conference präsentieren. Darüber hinaus wird Olema am Donnerstag, dem 20. Februar 2025, um 10:00 Uhr ET in einem virtuellen Gesprächsformat an Citis 2025 Virtual Oncology Leadership Summit teilnehmen.
Live-Webcasts beider Präsentationen sind über den Bereich Veranstaltungen und Präsentationen auf der Investor Relations-Website von Olema unter ir.olema.com zugänglich, wobei Aufzeichnungen mindestens 30 Tage nach den Veranstaltungen verfügbar sein werden.
- None.
- None.
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that management will participate in the following investor conferences:
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025 at 9:20 a.m. ET
Format: Virtual Presentation
Citi’s 2025 Virtual Oncology Leadership Summit
Date: Thursday, February 20, 2025 at 10 a.m. ET
Format: Virtual Fireside Chat
Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What investor conferences will Olema Pharmaceuticals (OLMA) attend in February 2025?
When is Olema's (OLMA) presentation at the Oppenheimer Healthcare Conference 2025?
How can investors access Olema's (OLMA) February 2025 conference presentations?
How long will Olema's (OLMA) February 2025 conference webcasts be available?
What is the format of Olema's (OLMA) presentation at Citi's 2025 Virtual Oncology Summit?
